2017
Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer
O’Connor M, Morrow MMB, Hunt KN, Boughey JC, Wahner-Roedler DL, Conners AL, Rhodes DJ, Hruska CB. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. EJNMMI Research 2017, 7: 5. PMID: 28091980, PMCID: PMC5237435, DOI: 10.1186/s13550-017-0255-6.Peer-Reviewed Original ResearchBreast cancerBenign lesionsMolecular subtypesBreast lesionsTumor molecular subtypeOverall diagnostic performancePathologic sizeAnalyzable patientsTumor extentMalignant tumorsLesion extentBlinded fashionLesion sizeSestamibiMolecular breastPatientsLesionsAlternative radiotracersLesion uptakeAssessment scoresROC analysisCancerInterest analysisDiagnostic performanceExamination one
2015
Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts.
Rhodes DJ, Hruska CB, Conners AL, Tortorelli CL, Maxwell RW, Jones KN, Toledano AY, O'Connor MK. Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. American Journal Of Roentgenology 2015, 204: 241-51. PMID: 25615744, PMCID: PMC4423604, DOI: 10.2214/ajr.14.13357.Peer-Reviewed Original ResearchConceptsCancer detection rateMolecular breast imagingDense breastsOverall cancer detection rateInvasive cancer detection rateDetection ratePositive predictive valueRadiation dose reductionAsymptomatic womenBilateral cancerDCIS detectionSupplemental screeningInvasive diseaseBiopsy rateDose reductionReduced radiation dosePredictive valueMolecular breastBreastScreening mammographyDiagnostic performanceRadiopharmaceutical activityCancerRadiation doseMammography